Exelixis (EXEL) Issues Positive Data from Cabozantinib Phase 3 in Advanced RCC
Tweet Send to a Friend
Exelixis, Inc. (Nasdaq: EXEL) announced the presentation of positive data from subgroup analyses of METEOR, the phase 3 pivotal trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
